Otsuka Pharmaceutical Company, Limited

Tsuyoshi Hirose

Kenji Maeda

Tetsuro Kikuchi

Katsura Tottori

Yasufumi Uwahodo

Shaun Jordan

Taro Iwamoto

Takao Nishi

Yohji Sakurai

Atsushi Mori

Nobuhiro Ikei

Nobuyuki Kurahashi

Masafumi Toda

Shaun Jordon

Takashi Miwa

Masahiro Kajiwara

The pharmaceutical composition of the present invention comprises () a carbostyril derivative and () a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HTreceptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

5-HT1A receptor subtype agonist

The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-sero-tonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamaza-pine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.

Carbostyril derivatives and mood stabilizers for treating mood disorders

The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HTreceptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

Method of treating cognitive impairments and schizophrenias

[object Object]

Method of treating neurodegenerative diseases

Method of treating down's syndrome

Method of treating autism

Method of treating panic disorder

Method of treating Attention Deficit Hyper-Activity Disorder

The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HTreceptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1):wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

5-HT1a receptor subtype agonist

Growing community of inventors

Tokushima, Japan

Tsuyoshi Hirose